Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK for trial

Redirecting to full article in 0 second(s)...
U.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.